American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
- PMID: 19716939
- PMCID: PMC4119170
- DOI: 10.1016/j.ygyno.2009.06.006
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
Erratum in
- Gynecol Oncol. 2010 Mar;116(3):592. Visvanathan, Kala [added]; Lippman, Scott M [added]; Hurley, Patricia [added]
Conflict of interest statement
No conflict of interest.
References
-
- National Cancer Institute. Breast Cancer Risk Assessment Tool. http://www.cancer.gov/bcrisktool.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
